ClinicalTrials.gg
CompletedNCT03535610EMBOSOFT IUpdated Sep 4, 2020

Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.

An interventional study of Uterine Embolization in Uterine Leiomyoma, sponsored by Scitech Produtos Medicos Ltda. Completed at 1 site in Brazil. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-09-04.

Sponsored by Scitech Produtos Medicos Ltda · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

To evaluate the therapeutic response to uterine artery embolization in 30 patients with leiomyoma using the microspheres Embosoft (Embosoft® - Scitech Medical).

02

Conditions studied

  • Uterine Leiomyoma

Keywords

  • Embolization
  • Uterine Leiomyoma
  • Embospheres
  • Microspheres
03

In context

Lead sponsor

Scitech Produtos Medicos Ltda is the lead sponsor of 13 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients from 18 to 50 years old;
  • symptomatic uterine intramural leiomyomas or multiple symptomatic leiomyomas in the presence of intramural;
  • patient agrees with study procedures;
  • patient signs the form.

Exclusion criteria

Exclusion Criteria:

  • asymptomatic women;
  • isolated adenomyosis, pediculated subserous myoma, submucous leiomyoma (50% of uterine cavity diameter), intraligamentous leiomyoma;
  • leiomyoma diameter higher than 10 cm;
  • leiomyoma above the umbilical scar;
  • endometrial neoplasia or hyperplasia or presence of any
  • pregnant or breast feeding women;
  • active vasculitis;
  • pelvic irradiation history;
  • uncontrolled coagulopathies;
  • renal insufficiency;
  • contrast allergy;
  • concomitant use of GnRH analogues.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Embolization

    Uterine Embolization with PVA Microspheres

    Device: Uterine Embolization

Interventions

  • DeviceUterine Embolization

    Uterine Embolization with PVA Microspheres

06

What researchers measure

Primary outcomes

  1. Uterine Volume Reduction

    Uterine Volume Reduction measured by MRI

    Time frame: 6 months

  2. Fibroid Reduction

    Fibroid Reduction measured by MRI

    Time frame: 6 months

Secondary outcomes

  1. Quality of Life Improvement

    Quality of Life Improvement measured by UFS-QOL

    Time frame: 6 months

  2. Ovarian Function

    Ovarian Function measured by Anti-Mullerian Hormon dosage pre and post-procedure

    Time frame: 6 months

07

Study locations

1 site
  • Certa Centro de Referência em Tratamentos Avançados
    São Paulo, SP 01401-002, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Feb 2020, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
May 24, 2018
StartActual
Aug 13, 2018
Primary completionActual
Feb 20, 2020
CompletionActual
May 20, 2020
Last update
Sep 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03535610
Lead sponsor
Scitech Produtos Medicos Ltda
Responsible party
Sponsor
First posted
May 24, 2018
Start date
Aug 13, 2018
Primary completion
Feb 20, 2020
Completion
May 20, 2020
Last update
Sep 4, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion